• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Microbiome Times

Finance

L’Oréal acquires research firm Lactobio

December 6, 2023 Microbiome Times

L’Oréal announced that it has completed the acquisition of Lactobio, a leading probiotic and microbiome research company based in Copenhagen. The strategic acquisition builds on 20 years of advanced research by L’Oréal into the microbiome scientific […]

Finance

Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines

December 5, 2023 Microbiome Times

Paris, FRANCE – December 5 2023 – Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful $30 million Series B […]

Pharma & Human Health

BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

November 29, 2023 Microbiome Times

Cambridge, MA & NESS ZIONA, Israel – November 29, 2023 – BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, […]

Finance

Vedanta Biosciences’ Key Microbiome Patents Fully Upheld in Three European Opposition Proceedings

November 29, 2023 Microbiome Times

Vedanta Biosciences, a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the Opposition Division of the European Patent Office (EPO) has fully upheld Vedanta’s foundational […]

Pharma & Human Health

Morinaga Milk’s Probiotic Receives Approval of Individual Recognized Registration in South Korea

November 28, 2023 Microbiome Times

Morinaga Milk Industry Co., Ltd. a leading Japanese dairy product company, announced its proprietary probiotic strain Bifidobacterium breve B-3 has received the approval of Individual Recognized Registration in South Korea for its clinically demonstrated efficacy in body fat […]

Finance

Boehringer Ingelheim acquires bacterial cancer therapy specialist T3 Pharma

November 22, 2023 Microbiome Times

Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF. T3 Pharma has developed a proprietary therapy […]

Pharma & Human Health

Initial patient dosed in Phase 2a clinical trial evaluating first-in-class human milk-based therapy

November 15, 2023 Microbiome Times

In a breakthrough for human milk science, researchers at City of Hope, Los Angeles, have dosed the first patient in a Phase 2a clinical trial evaluating a novel therapy for blood cancer patients undergoing allogeneic […]

Finance

Synlogic reports Q3 results, including underwritten public offering of $21.0M and $2.5M milestone payment from Roche

November 11, 2023 Microbiome Times

Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today reported financial results for the third quarter ended September 30, 2023, and provided […]

Pharma & Human Health

Mammalian cells may consume bacteria-killing viruses to promote cellular health

November 9, 2023 Microbiome Times

Bacteriophages are viruses that infect and kill bacteria, their natural hosts. But from a macromolecular viewpoint, phages can be viewed as nutritionally enriched packets of nucleotides wrapped in an amino acid shell. A study published […]

Pharma & Human Health

Canada approves gut-brain axis health claims for Chr. Hansen probiotic strain

November 8, 2023 Microbiome Times

Health Canada authorizes functional claims that the probiotic strain DDS-1® “helps alleviate perceived stress and improve irritable bowel syndrome-related quality of life in adolescents and adults” The ‘gut-brain axis’ has become one of the most […]

Pharma & Human Health

MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT

November 7, 2023 Microbiome Times

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company developing Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, announced that the first patient has been treated as part of its Phase […]

Posts navigation

« 1 … 10 11 12 … 76 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
sign up

Sign up to the Microbiome Times newsletter